Menu Search
Equities

Kindstar Globalgene Technology Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
9960:HKG.HZ

Kindstar Globalgene Technology Inc

Actions
  • Price (HKD)1.20
  • Today's Change0.00 / 0.00%
  • Shares traded41.00k
  • 1 Year change-1.64%
  • Beta0.5869
Data delayed at least 15 minutes, as of Feb 16 2026 04:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Kindstar Globalgene Technology Inc is an investment holding company engaged in the provision of clinical testing services. The Company includes nine segments. The Hematology Testing segment includes testing services related to blood diseases. The Genetic Diseases and Rare Diseases segment includes testing services from the rare disease. The Infectious Diseases segment includes testing services from the infection department. The Oncology segment includes testing related to oncology diseases. The Neurology segment includes testing services related to neurological diseases. The Maternity-Related Diseases segment includes testing services related to maternity. The Routine Testing segment conducts routine tests for the doctors’ daily diagnoses. The Scientific Research Services and Cro segment includes research and development services. The Others segment provides other miscellaneous testing services.

  • Revenue in HKD (TTM)1.03bn
  • Net income in HKD-116.02m
  • Incorporated2007
  • Employees3.16k
  • Location
    Kindstar Globalgene Technology IncEast Lake High Tech ZoneBiolake D2-1, 666 Gaoxin RoadWUHAN ChinaCHN
  • Websitehttps://www.kindstar.com.cn/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.